Tharimmune (NASDAQ:THAR) Trading Down 0.5% – Here’s What Happened

Tharimmune, Inc. (NASDAQ:THAR)’s stock price fell 0.5% during mid-day trading on Tuesday . The company traded as low as $3.92 and last traded at $4.05. 588,151 shares were traded during mid-day trading, a decline of 60% from the average session volume of 1,476,877 shares. The stock had previously closed at $4.07.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tharimmune in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Tharimmune Stock Down 2.5%

The firm has a market capitalization of $149.03 million, a price-to-earnings ratio of -0.99 and a beta of 1.43. The business’s fifty day moving average is $4.17 and its 200 day moving average is $3.40.

Institutional Investors Weigh In On Tharimmune

Several institutional investors have recently bought and sold shares of THAR. Aristides Capital LLC acquired a new stake in shares of Tharimmune in the fourth quarter valued at approximately $253,000. Feynman Point Asset Management LLC acquired a new position in Tharimmune during the fourth quarter worth $1,314,000. Blair William & Co. IL acquired a new position in Tharimmune during the fourth quarter worth $831,000. Clear Street Group Inc. bought a new position in Tharimmune in the fourth quarter valued at $5,066,000. Finally, Marshall Wace LLP bought a new position in Tharimmune in the fourth quarter valued at $1,030,000. Institutional investors own 1.16% of the company’s stock.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc for the development of proprietary targeted biologics; and Washington University in St.